ZBIO
Zenas BioPharma, Inc. NASDAQ Listed Sep 13, 2024$25.87
+4.86%
vs $24.67
Mkt Cap $1.2B
52w Low $9.14
49.2% of range
52w High $43.17
50d MA $19.38
200d MA $24.77
P/E (TTM)
—
EV/EBITDA
—
P/B
4.8x
Debt/Equity
0.3x
ROE
-156.0%
P/FCF
-6.7x
RSI (14)
79.70
ATR (14)
$1.58
Beta
-0.51
50d MA
$19.38
200d MA
$24.77
Avg Volume
772.3K
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
North Building · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | TNS | -1.47 | -1.46 | +1.0% | 19.93 | +0.9% | -5.2% | -3.0% | -7.8% | +5.5% | +9.6% | — |
| Mar 16, 2026 | TNS | -1.00 | -1.10 | -9.8% | 23.23 | +1.0% | +1.1% | -1.9% | +1.5% | -4.6% | -7.5% | — |
| Nov 12, 2025 | TNS | -0.87 | -1.22 | -40.2% | 35.80 | -1.6% | -0.4% | -1.9% | +2.5% | +0.9% | +2.6% | — |
| Aug 12, 2025 | TNS | -1.02 | -1.25 | -22.5% | 15.90 | +1.9% | +5.1% | +0.3% | +0.4% | +2.7% | -8.3% | — |
| May 15, 2025 | TNS | -1.11 | -0.80 | +27.9% | 9.74 | +0.1% | +7.5% | +5.2% | +4.3% | -4.7% | +4.7% | — |
| Mar 25, 2025 | TNS | -0.92 | -3.99 | -333.7% | 9.11 | -0.9% | -11.5% | -0.4% | +1.7% | -3.3% | -3.8% | — |
| Nov 12, 2024 | TNS | -9.33 | -5.02 | +46.2% | 20.61 | +0.0% | -7.3% | -1.9% | -8.6% | -11.8% | -3.9% | — |
| Jun 30, 2024 | TNS | — | -0.99 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | TNS | — | -0.73 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | TNS | — | -0.64 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | TNS | — | 0.85 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | TNS | — | -0.76 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.50 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17 | Citigroup | Maintains | Buy → Buy | — | $23.23 | $23.46 | +1.0% | +1.1% | -1.9% | +1.5% | -4.6% | -7.5% |
| Mar 17 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $23.23 | $23.46 | +1.0% | +1.1% | -1.9% | +1.5% | -4.6% | -7.5% |
| Mar 17 | Guggenheim | Maintains | Buy → Buy | — | $23.23 | $23.46 | +1.0% | +1.1% | -1.9% | +1.5% | -4.6% | -7.5% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.23 | $23.46 | +1.0% | +1.1% | -1.9% | +1.5% | -4.6% | -7.5% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.48 | $22.48 | +0.0% | -4.4% | +8.3% | +12.2% | +1.1% | +1.4% |
| Jan 6 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $16.61 | $15.75 | -5.2% | -8.5% | +8.6% | -0.6% | -2.0% | +23.0% |
| Dec 22 | Wedbush | Maintains | Outperform → Outperform | — | $36.15 | $36.16 | +0.0% | +17.1% | +1.1% | +0.8% | -1.6% | -8.1% |
| Nov 13 | Morgan Stanley | Maintains | Overweight → Overweight | — | $35.80 | $35.22 | -1.6% | -0.4% | -1.9% | +2.5% | +0.9% | +2.6% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.80 | $32.00 | +0.6% | -5.1% | -7.2% | +6.7% | +4.6% | +0.3% |
| Oct 28 | Citigroup | Maintains | Buy → Buy | — | $31.80 | $32.00 | +0.6% | -5.1% | -7.2% | +6.7% | +4.6% | +0.3% |
| Oct 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $31.80 | $32.00 | +0.6% | -5.1% | -7.2% | +6.7% | +4.6% | +0.3% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.90 | $26.21 | +1.2% | +7.2% | -4.2% | -0.2% | -2.6% | +4.4% |
| Oct 9 | Wedbush | Maintains | Outperform → Outperform | — | $25.90 | $26.21 | +1.2% | +7.2% | -4.2% | -0.2% | -2.6% | +4.4% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.74 | $9.75 | +0.1% | +7.5% | +5.2% | +4.3% | -4.7% | +4.7% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.25 | $7.49 | +3.3% | +13.2% | +6.3% | -5.5% | +2.2% | -6.3% |
| Mar 12 | Guggenheim | Maintains | Buy → Buy | — | $7.25 | $7.49 | +3.3% | +13.2% | +6.3% | -5.5% | +2.2% | -6.3% |
| Dec 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $9.50 | $9.32 | -1.9% | -3.6% | +1.0% | -3.6% | -1.7% | +8.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | MOULDER LEON O JRDir/Off | Chief Executive Officer | Buy | 60,000 | $16.88 | $1.0M | 96,928 | +5.50% | -1.27% |
8-K · 5.02
!!! Very High
Zenas BioPharma, Inc. -- 8-K 5.02: Executive Change
May 13
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
ZBIO secured underwriting services from Jefferies LLC, likely indicating an upcoming equity offering that could dilute shareholders but raise capital for operations or acquisitions.
Mar 31
8-K
Unknown — 8-K Filing
Zenas Biopharma's successful Phase 3 INDIGO trial validates its lead autoimmune therapy candidate, positioning it for potential FDA approval and commercialization that could drive significant revenue growth and stock appreciation.
Mar 16
8-K · 5.02
!!! Very High
Zenas BioPharma, Inc. -- 8-K 5.02: Executive Change
Zenas BioPharma adopted an annual discretionary cash bonus plan (STI Plan) for employees and executives, with Board oversight of executive compensation and CEO administration for other eligible staff members.
Feb 13
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 9,082,000 | $178M | Added | Mar 2026 |
| 2 | Fairmount Funds Management Llc | 2,359,025 | $46M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 1,245,391 | $24M | New | Mar 2026 |
| 4 | Woodline Partners Lp | 590,525 | $12M | New | Mar 2026 |
| 5 | Marshall Wace, Llp | 501,928 | $10M | Added | Mar 2026 |
| 6 | Millennium Management | 476,818 | $9M | Added | Mar 2026 |
| 7 | Morgan Stanley | 256,670 | $9M | Added | Dec 2025 |
| 8 | Bank Of America Corp /de/ | 388,347 | $8M | Added | Mar 2026 |
| 9 | Ubs Group Ag | 367,405 | $7M | Added | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 275,056 | $5M | Added | Mar 2026 |
| 11 | Vanguard Portfolio Management Llc | 251,410 | $5M | New | Mar 2026 |
| 12 | Walleye Capital Llc | 250,464 | $5M | New | Mar 2026 |
| 13 | Ia Global Asset Management Inc. | 215,830 | $4M | New | Mar 2026 |
| 14 | Northern Trust Corp | 194,640 | $4M | Added | Mar 2026 |
| 15 | Invesco Ltd. | 113,479 | $2M | Reduced | Mar 2026 |
| 16 | Atom Investors Lp | 107,016 | $2M | New | Mar 2026 |
| 17 | Susquehanna International Group, Llp | 85,005 | $2M | Added | Mar 2026 |
| 18 | Nuveen, Llc | 67,770 | $1M | Added | Mar 2026 |
| 19 | Citadel Advisors Llc | 66,870 | $1M | Added | Mar 2026 |
| 20 | Bank Of New York Mellon Corp | 60,864 | $1M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.16B
Enterprise Value
$892.6M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.03x
P/B
4.78x
P/S
—
P/FCF
-6.71x
EV/EBITDA
—
Shares Out
44.7M
Financials (TTM)
Revenue
$0
Net Income
-$425.2M
EBITDA
-$408.4M
Free Cash Flow
-$172.4M
Op Cash Flow
-$172.3M
EPS Basic
$-8.44
EPS Diluted
$-9.10
EPS Forward
$-4.83
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$383.6M
Total Liab.
$141.5M
Total Equity
$242.1M
Cash
$343.2M
LT Debt
$78.6M
Book Value/Sh
$5.41
Debt/Equity
0.33x
Current Ratio
5.61
Quick Ratio
5.61
Returns & Growth
ROE
-156.0%
ROA
-98.5%
ROIC
-65.6%
Rev Growth YoY
+100.0%
EPS Growth YoY
-124.5%
Price Returns
2W
-2.6%
1M
-4.8%
3M
-30.2%
6M
-52.6%
12M
+93.3%
Technicals
52W High
$43.17
52W Low
$9.14
50d MA
$19.38
200d MA
$24.77
RSI (14)
79.70
ATR (14)
$1.58
Beta
-0.51
Avg Volume
772K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Dec 24, 2019
Analyst Price Targets
Consensus
$33.50
High
$48.00
Low
$19.00
Median
$33.50
Data updated apr 27, 2026 11:32am
· Source: financialmodelingprep.com